A Phase 3 interventional study of Thalidomide and Bortezomib in Multiple Myeloma, sponsored by Janssen Scientific Affairs, LLC. Completed at 23 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Janssen Scientific Affairs, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies testing thalidomide in Multiple Myeloma — 2 open to participants now, 6 under way, 2 of them phase 3. Thalidomide · Multiple Myeloma.
Among the 93 studies testing thalidomide in Multiple Myeloma, this one is the 22nd largest by enrollment of the 87 interventional ones that give a count, is one of 2 that started in 2012, is one of 32 in phase 3, and was the 77th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →2 of the 93 studies testing thalidomide in Multiple Myeloma are open now, in 1 country. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Juan Du · Sites in China
Ages 18–75
By country, each count listing its studies:
Thalidomide: first FDA approval 1998 (THALOMID), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 54 · Phase 3 34 · Phase 4 2
First in 1998; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 256 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 80 across the 87 interventional studies. Of the 72 that completed or were terminated, 24 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 93 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Scientific Affairs, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Scientific Affairs, LLC is the lead sponsor of 41 studies on the registry; 2 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
126 studies in Multiple Myeloma by Johnson & Johnson: 13 open now, 33 under way, 12 of them phase 3. Of 82 finished, 33 (40%) have results posted.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 26th largest by enrollment of the 100 interventional ones that give a count, is one of 3 that started in 2012, is one of 35 in phase 3, and was the 45th registered.
Johnson & Johnson’s Multiple Myeloma studies by the year they started, since 1995.
3 of the studies testing thalidomide in Multiple Myeloma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00572169Phase 3University of ArkansasUARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy | 2027-08 |
| NCT03004287University of Arkansas2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy | 2027-10 |
| NCT00869232University of ArkansasUARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 93 studies testing thalidomide in Multiple Myeloma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 126 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if bortezomib when added to consolidation treatment with thalidomide and prednisolone leads to an improved response in patients with multiple myeloma who have undergone autologous stem cell transplant and initial treatment with bortezomib, cyclophosphamide, and dexamethasone.
This is an open-label (patients will know the identity of study treatments), randomized (patients will be assigned by chance to different treatments) study of bortezomib administered as consolidation therapy (therapy given once a remission is achieved) with thalidomide and prednisolone versus thalidomide and prednisolone alone in previously untreated patients with multiple myeloma. Multiple myeloma is a cancer of your plasma cells, a type of white blood cell present in your bone marrow. Patients in this study will receive initial therapy with bortezomib, cyclophosphamide, and dexamethasone (referred to as VCD induction therapy) and will undergo autologous stem cell transplant (ASCT) (a procedure where patients receive an infusion of immature blood cells [stem cells] from their own body to replenish the body's supply of healthy blood-forming cells) before randomization to one of two treatments: Treatment A (thalidomide for up to 12 months or until disease progression and prednisolone on alternate days continued indefinitely or until disease progression) or Treatment B (bortezomib for 32 weeks in addition to thalidomide up to 12 months or until disease progression and prednisolone on alternate days, continued indefinitely or until disease progression.
Throughout the study, the patient's response to therapy will be assessed according to protocol-defined efficacy evaluations and by implementing defined disease response criteria (International Myeloma Working Group [IMWG] criteria). Safety will be evaluated throughout the study. Follow up for progression-free survival (PFS) and overall survival (OS) will be conducted from time of randomization to 3 years post-randomization.
Two interim analyses are planned. The final analysis will be conducted after all patients have completed 12-month consolidation treatment phase or discontinued. The primary endpoint of number and percent of patients with complete response and very good partial response defined by IMWG criteria for multiple myeloma will be examined in the interim and final analyses after approximately 12 months of consolidation therapy. At the completion of the study, updated analyses of PFS and OS will be performed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bortezomib (Velcade) 1.3 milligram per square meter (mg/m\^2) subcutaneously (SC) on Days 1, 4, 8, and 11; cyclophosphamide 300 mg/m\^2 orally on Days 1, 8, and 15; and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 in three 21-day treatment cycles. Participants who completed induction phase entered into the consolidation treatment phase.
Drug: Bortezomib · Drug: Cyclophosphamide · Drug: Dexamethasone
Thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.
Drug: Thalidomide · Drug: Prednisolone
Bortezomib 1.3 mg/m\^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.
Drug: Thalidomide · Drug: Bortezomib · Drug: Prednisolone
Thalidomide 100 mg tablet, orally.
Bortezomib 1.3 milligram per square meter (mg/m\^2) solution for injection subcutaneously (SC).
Cyclophosphamide 300 mg/m\^2 orally.
Dexamethasone 20 mg orally.
Prednisolone 50 mg orally.
Consolidation Phase: Percentage of Participants With Complete Response (CR) and Very Good Partial Response (VGPR) at Month 12
CR as per IMWG criteria is defined as negative immunofixation on the serum and urine and disappearance of soft tissue plasmacytomas and less than (\<) 5 percent plasma cells in bone marrow. VGPR as per IMWG criteria is defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90 percent or greater reduction in serum M-protein plus urine M-protein level \<100 milligram (mg) per 24 hours.
Time frame: Month 12
Consolidation Phase: Percentage of Participants With Complete Response (CR) at Months 3, 6, 9 and 12
CR as per IMWG criteria is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and \<5 percent plasma cells in bone marrow.
Time frame: Months 3, 6, 9 and 12
Consolidation Phase: Percentage of Participants With Stringent Complete Response (sCR) at Months 3, 6, 9 and 12
sCR as per IMWG criteria is CR plus normal free light chain (FLC) ratio and absence of clonal cells in bone marrow. CR is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and \<5 percent plasma cells in bone marrow.
Time frame: Months 3, 6, 9 and 12
Progression Free Survival (PFS)
PFS, calculated as the time between randomization to disease progression or death (regardless of cause), whichever occurred first. Progressive disease as per IMWG criteria: increase of \>= 25 percent from lowest response level in Serum M-component and/or (the absolute increase must be \>=0.5 gram per deciliter \[g/dL\]) Urine M-component and/or (the absolute increase must be \>=200 mg/24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase must be \>10 mg/dL. Bone marrow plasma cell percentage: the absolute percent must be \>=10 percent. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL or 2.65 millimole per liter (mmol/L) that can be attributed solely to the plasma cell proliferative disorder.
Time frame: Baseline until progressive disease (up to 5 years)
Disease-free Survival (DFS)
DFS, defined as the duration from the start of CR to the time of relapse from CR. DFS applied only to participants in CR. CR as per IMWG criteria is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and \<5 percent plasma cells in bone marrow. Relapse from CR: reappearance of serum or urine M-protein by immunofixation or electrophoresis; development of \>= 5 percent plasma cells in the bone marrow; appearance of any other sign of progression (ie, new plasmacytoma, lytic bone lesion, or hypercalcaemia).
Time frame: Up to 5 years
Overall Survival (OS)
OS was defined as the time between randomization and death. Death of a participant regardless of the cause was considered as an event.
Time frame: Up to 5 years
Consolidation Phase: Change From Baseline in AQOL-6D Scores at the End of the Consolidation Phase
The assessment of quality of life-6D (AQoL-6D) is a multi-attribute health-related quality of life instrument (QoL). It comprises dimension scores for independent living, relationships, mental health, coping, pain, senses, and utility score for AQol-6D. Each scale ranges between 1 (best QoL) and -0.04 (worst possible QoL).
Time frame: Baseline, Month 12
Consolidation Phase: Change From Baseline in FACT/GOG-NTX Total Score at the End of the Consolidation Phase
Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX) consists of 10 items and evaluates symptoms and concerns associated specifically with chemotherapy-induced neuropathy. 1 FACT/GOG-NTX total score has a range of 0 to 108 with a higher score indicating better quality of life.
Time frame: Baseline, Month 12
| Milestone | Bortezomib + Cyclophosphamide + Dexamethasone (VCD Induction) | Thalidomide + Prednisolone (TP Consolidation) | Bortezomib + Thalidomide + Prednisolone (VTP Consolidation) |
|---|---|---|---|
| Started | 256 | 0 | 0 |
| Treated | 254 | 0 | 0 |
| Completed | 203 | 0 | 0 |
| Not completed | 53 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 0 | 0 |
| Withdrew: Adverse event | 14 | 0 | 0 |
| Withdrew: Death | 6 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 0 | 0 |
| Withdrew: Physician decision | 14 | 0 | 0 |
| Withdrew: Progressive disease | 8 | 0 | 0 |
| Withdrew: Other | 5 | 0 | 0 |
| Milestone | Bortezomib + Cyclophosphamide + Dexamethasone (VCD Induction) | Thalidomide + Prednisolone (TP Consolidation) | Bortezomib + Thalidomide + Prednisolone (VTP Consolidation) |
|---|---|---|---|
| Started | 0 | 100 | 103 |
| Safety population | 0 | 99 | 103 |
| Completed | 0 | 79 | 80 |
| Not completed | 0 | 21 | 23 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Other | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 5 | 4 |
| Withdrew: Progressive disease | 0 | 6 | 3 |
| Withdrew: Death | 0 | 6 | 11 |
CR as per IMWG criteria is defined as negative immunofixation on the serum and urine and disappearance of soft tissue plasmacytomas and less than (\<) 5 percent plasma cells in bone marrow. VGPR as per IMWG criteria is defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90 percent or greater reduction in serum M-protein plus urine M-protein level \<100 milligram (mg) per 24 hours.
| percentage of participants | Thalidomide + Prednisolone [TP Consolidation] | Bortezomib + Thalidomide + Prednisolone [VTP Consolidation] |
|---|---|---|
| Consolidation Phase: Percentage of Participants With Complete Response (CR) and Very Good Partial Response (VGPR) at Month 12 | 81.3 | 92.9 |
CR as per IMWG criteria is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and \<5 percent plasma cells in bone marrow.
| percentage of participants | Thalidomide + Prednisolone [TP Consolidation] | Bortezomib + Thalidomide + Prednisolone [VTP Consolidation] |
|---|---|---|
| Month 3 | 36.5 | 36.7 |
| Month 6 | 44.8 | 44.9 |
| Month 9 | 49.0 | 52.0 |
| Month 12 | 51.0 | 53.1 |
sCR as per IMWG criteria is CR plus normal free light chain (FLC) ratio and absence of clonal cells in bone marrow. CR is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and \<5 percent plasma cells in bone marrow.
| percentage of participants | Thalidomide + Prednisolone [TP Consolidation] | Bortezomib + Thalidomide + Prednisolone [VTP Consolidation] |
|---|---|---|
| Month 3 | 20.8 | 23.5 |
| Month 6 | 27.1 | 28.6 |
| Month 9 | 26.0 | 30.6 |
| Month 12 | 26.0 | 28.6 |
PFS, calculated as the time between randomization to disease progression or death (regardless of cause), whichever occurred first. Progressive disease as per IMWG criteria: increase of \>= 25 percent from lowest response level in Serum M-component and/or (the absolute increase must be \>=0.5 gram per deciliter \[g/dL\]) Urine M-component and/or (the absolute increase must be \>=200 mg/24 hour. Only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase must be \>10 mg/dL. Bone marrow plasma cell percentage: the absolute percent must be \>=10 percent. Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas. Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL or 2.65 millimole per liter (mmol/L) that can be attributed solely to the plasma cell proliferative disorder.
| months | Thalidomide + Prednisolone [TP Consolidation] | Bortezomib + Thalidomide + Prednisolone [VTP Consolidation] |
|---|---|---|
| Progression Free Survival (PFS) | 22.05 (18.46 to 25.49) | 22.51 (18.56 to 24.15) |
DFS, defined as the duration from the start of CR to the time of relapse from CR. DFS applied only to participants in CR. CR as per IMWG criteria is negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and \<5 percent plasma cells in bone marrow. Relapse from CR: reappearance of serum or urine M-protein by immunofixation or electrophoresis; development of \>= 5 percent plasma cells in the bone marrow; appearance of any other sign of progression (ie, new plasmacytoma, lytic bone lesion, or hypercalcaemia).
| months | Thalidomide + Prednisolone [TP Consolidation] | Bortezomib + Thalidomide + Prednisolone [VTP Consolidation] |
|---|---|---|
| Disease-free Survival (DFS) | 18.53 (11.24 to 23.36) | 13.37 (10.18 to 20.96) |
OS was defined as the time between randomization and death. Death of a participant regardless of the cause was considered as an event.
| months | Thalidomide + Prednisolone [TP Consolidation] | Bortezomib + Thalidomide + Prednisolone [VTP Consolidation] |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
The assessment of quality of life-6D (AQoL-6D) is a multi-attribute health-related quality of life instrument (QoL). It comprises dimension scores for independent living, relationships, mental health, coping, pain, senses, and utility score for AQol-6D. Each scale ranges between 1 (best QoL) and -0.04 (worst possible QoL).
| units on a scale | Thalidomide + Prednisolone [TP Consolidation] | Bortezomib + Thalidomide + Prednisolone [VTP Consolidation] |
|---|---|---|
| Independent Living | 0.15 ± 0.335 | 0.14 ± 0.397 |
| Relationships | 0.06 ± 0.300 | 0.05 ± 0.296 |
| Mental Health | 0.18 ± 0.319 | 0.18 ± 0.270 |
| Coping | 0.08 ± 0.278 | 0.05 ± 0.237 |
| Pain | 0.20 ± 0.373 | 0.20 ± 0.395 |
| Senses | 0.03 ± 0.140 | 0.00 ± 0.137 |
| AQoL-6D Utility score | 0.11 ± 0.216 | 0.11 ± 0.213 |
Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX) consists of 10 items and evaluates symptoms and concerns associated specifically with chemotherapy-induced neuropathy. 1 FACT/GOG-NTX total score has a range of 0 to 108 with a higher score indicating better quality of life.
| units on a scale | Thalidomide + Prednisolone [TP Consolidation] | Bortezomib + Thalidomide + Prednisolone [VTP Consolidation] |
|---|---|---|
| Consolidation Phase: Change From Baseline in FACT/GOG-NTX Total Score at the End of the Consolidation Phase | 2.9 ± 19.68 | 1.0 ± 19.69 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bortezomib + Cyclophosphamide + Dexamethasone (VCD Induction) | — | 88/254 (34.6%) | 233/254 (91.7%) |
| Thalidomide + Prednisolone (TP Consolidation) | — | 22/99 (22.2%) | 95/99 (96%) |
| Bortezomib + Thalidomide + Prednisolone (VTP Consolidation) | — | 28/103 (27.2%) | 96/103 (93.2%) |
| Event | Bortezomib + Cyclophosphamide + Dexamethasone (VCD Induction) | Thalidomide + Prednisolone (TP Consolidation) | Bortezomib + Thalidomide + Prednisolone (VTP Consolidation) |
|---|---|---|---|
| PneumoniaInfections and infestations | 5/254 | 6/99 | 7/103 |
| PyrexiaGeneral disorders | 12/254 | 1/99 | 3/103 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 11/254 | 0/99 | 0/103 |
| Herpes ZosterInfections and infestations | 0/254 | 2/99 | 2/103 |
| Lobar PneumoniaInfections and infestations | 1/254 | 2/99 | 0/103 |
| Respiratory Tract InfectionInfections and infestations | 1/254 | 2/99 | 1/103 |
| Back PainMusculoskeletal and connective tissue disorders | 4/254 | 2/99 | 0/103 |
| Lower Respiratory Tract InfectionInfections and infestations | 4/254 | 1/99 | 2/103 |
| Rhinovirus InfectionInfections and infestations | 0/254 | 0/99 | 2/103 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 2/254 | 1/99 | 2/103 |
| Event | Bortezomib + Cyclophosphamide + Dexamethasone (VCD Induction) | Thalidomide + Prednisolone (TP Consolidation) | Bortezomib + Thalidomide + Prednisolone (VTP Consolidation) |
|---|---|---|---|
| ConstipationGastrointestinal disorders | 91/254 | 38/99 | 29/103 |
| Peripheral Sensory NeuropathyNervous system disorders | 62/254 | 38/99 | 38/103 |
| Upper Respiratory Tract InfectionInfections and infestations | 29/254 | 32/99 | 39/103 |
| NauseaGastrointestinal disorders | 82/254 | 10/99 | 12/103 |
| Neuropathy PeripheralNervous system disorders | 34/254 | 24/99 | 30/103 |
| Weight IncreasedInvestigations | 7/254 | 26/99 | 17/103 |
| FatigueGeneral disorders | 61/254 | 18/99 | 16/103 |
| InsomniaPsychiatric disorders | 56/254 | 22/99 | 13/103 |
| Oedema PeripheralGeneral disorders | 44/254 | 15/99 | 16/103 |
| NeuralgiaNervous system disorders | 19/254 | 14/99 | 16/103 |
Baseline population was defined as all enrolled participants who received at least 1 non-zero dose of any study drug in the induction phase.
| Age, Continuous(years) | Bortezomib + Cyclophosphamide + Dexamethasone (VCD Induction) |
|---|---|
| Mean | 57.8 ± 7.76 |
| Sex: Female, Male(Participants) | Bortezomib + Cyclophosphamide + Dexamethasone (VCD Induction) |
|---|---|
| Female | 109 |
| Male | 145 |
| Region of Enrollment(Participants) | Bortezomib + Cyclophosphamide + Dexamethasone (VCD Induction) |
|---|---|
| Australia | 207 |
| China | 17 |
| Republic of Korea | 30 |
Ran from Jan 2012 to primary completion in Dec 2015, 47 months.
Results were first posted in Feb 2017, 1 year 1 month after primary completion.
Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 47 months is close to that.
Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Thalidomide · Bortezomib · Cyclophosphamide · Dexamethasone · Prednisolone
Janssen Scientific Affairs, LLC →